# Sarcoma Diagnosis and Treatment

**Type:** Topics  
**Canonical URL:** https://scholariq.org/topics/sarcoma-diagnosis-and-treatment/

## Facts

| Field | Value |
| --- | --- |
| Description | This cluster of papers focuses on research and treatment related to various types of sarcomas, including osteosarcoma, soft tissue sarcoma, Ewing's sarcoma, rhabdomyosarcoma, and synovial sarcoma. It covers topics such as chemotherapy, prognostic factors, genomic characterization, and the development of clinical practice guidelines for diagnosis and treatment. The papers also discuss the use of immunohistochemical markers for diagnostic purposes. |
| Domain | Health Sciences |
| Field | Medicine |
| OpenAlex ID | t10253 |
| Works | 319 |

## Topic papers all

Showing 15 of 319.

- [Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up](https://scholariq.org/papers/soft-tissue-and-visceral-sarcomas-esmo-euracan-clinical-practice-guidelines-for/)
- [Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity.](https://scholariq.org/papers/randomized-prospective-study-of-the-benefit-of-adjuvant-radiation-therapy-in-the/)
- [Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial](https://scholariq.org/papers/pembrolizumab-in-advanced-soft-tissue-sarcoma-and-bone-sarcoma-sarc028-a/)
- [Soft Tissue Sarcoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology](https://scholariq.org/papers/soft-tissue-sarcoma-version-2-2022-nccn-clinical-practice-guidelines-in-oncology/)
- [Soft tissue and visceral sarcomas: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up☆](https://scholariq.org/papers/soft-tissue-and-visceral-sarcomas-esmo-euracan-genturis-clinical-practice/)
- [Mesenchymal Stromal Cells: Current Understanding and Clinical Status](https://scholariq.org/papers/mesenchymal-stromal-cells-current-understanding-and-clinical-status/)
- [Soft-Tissue Sarcomas in Adults](https://scholariq.org/papers/soft-tissue-sarcomas-in-adults/)
- [Advancing therapy for osteosarcoma](https://scholariq.org/papers/advancing-therapy-for-osteosarcoma/)
- [Neurofibromatosis type 1](https://scholariq.org/papers/neurofibromatosis-type-1/)
- [Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial](https://scholariq.org/papers/efficacy-and-safety-of-trabectedin-or-dacarbazine-for-metastatic-liposarcoma-or/)
- [Molecular International Prognostic Scoring System for Myelodysplastic Syndromes](https://scholariq.org/papers/molecular-international-prognostic-scoring-system-for-myelodysplastic-syndromes/)
- [Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing](https://scholariq.org/papers/identification-of-recurrent-nab2-stat6-gene-fusions-in-solitary-fibrous-tumor-by/)
- [Gastrointestinal stromal tumours: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up](https://scholariq.org/papers/gastrointestinal-stromal-tumours-esmo-euracan-clinical-practice-guidelines-for/)
- [Randomized Phase II Study of Gemcitabine and Docetaxel Compared With Gemcitabine Alone in Patients With Metastatic Soft Tissue Sarcomas: Results of Sarcoma Alliance for Research Through Collaboration Study 002](https://scholariq.org/papers/randomized-phase-ii-study-of-gemcitabine-and-docetaxel-compared-with-gemcitabine/)
- [Soft Tissue Sarcoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology](https://scholariq.org/papers/soft-tissue-sarcoma-version-2-2018-nccn-clinical-practice-guidelines-in-oncology/)

## Topic primary papers

Showing 15 of 162.

- [Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up](https://scholariq.org/papers/soft-tissue-and-visceral-sarcomas-esmo-euracan-clinical-practice-guidelines-for/)
- [Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity.](https://scholariq.org/papers/randomized-prospective-study-of-the-benefit-of-adjuvant-radiation-therapy-in-the/)
- [Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial](https://scholariq.org/papers/pembrolizumab-in-advanced-soft-tissue-sarcoma-and-bone-sarcoma-sarc028-a/)
- [Soft Tissue Sarcoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology](https://scholariq.org/papers/soft-tissue-sarcoma-version-2-2022-nccn-clinical-practice-guidelines-in-oncology/)
- [Soft tissue and visceral sarcomas: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up☆](https://scholariq.org/papers/soft-tissue-and-visceral-sarcomas-esmo-euracan-genturis-clinical-practice/)
- [Soft-Tissue Sarcomas in Adults](https://scholariq.org/papers/soft-tissue-sarcomas-in-adults/)
- [Advancing therapy for osteosarcoma](https://scholariq.org/papers/advancing-therapy-for-osteosarcoma/)
- [Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial](https://scholariq.org/papers/efficacy-and-safety-of-trabectedin-or-dacarbazine-for-metastatic-liposarcoma-or/)
- [Randomized Phase II Study of Gemcitabine and Docetaxel Compared With Gemcitabine Alone in Patients With Metastatic Soft Tissue Sarcomas: Results of Sarcoma Alliance for Research Through Collaboration Study 002](https://scholariq.org/papers/randomized-phase-ii-study-of-gemcitabine-and-docetaxel-compared-with-gemcitabine/)
- [Soft Tissue Sarcoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology](https://scholariq.org/papers/soft-tissue-sarcoma-version-2-2018-nccn-clinical-practice-guidelines-in-oncology/)
- [Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort](https://scholariq.org/papers/survival-and-prognosis-with-osteosarcoma-outcomes-in-more-than-2000-patients-in/)
- [Current and future therapeutic approaches for osteosarcoma](https://scholariq.org/papers/current-and-future-therapeutic-approaches-for-osteosarcoma/)
- [Biology and Therapeutic Advances for Pediatric Osteosarcoma](https://scholariq.org/papers/biology-and-therapeutic-advances-for-pediatric-osteosarcoma/)
- [Bone sarcomas: ESMO–PaedCan–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up](https://scholariq.org/papers/bone-sarcomas-esmo-paedcan-euracan-clinical-practice-guidelines-for-diagnosis/)
- [The Epidemiology of Sarcoma](https://scholariq.org/papers/the-epidemiology-of-sarcoma/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.